Compare Incyte Corporation (INCY) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Weibo Corp — how do they compare? Incyte Corporation trades at $120.76 (market cap $24.54B), while Weibo Corp trades at $7.74 (market cap $1.93B). The key difference: Incyte Corporation is far larger — about 12.7× Weibo Corp's market cap, and Weibo Corp pays a 7.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WB | |
|---|---|---|
Market Cap | $24.54B | $1.93B |
Sector | Health | Media |
52-Week High | $129.93 | $12.83 |
52-Week Low | $81.61 | $7.20 |
Enterprise Value | $20.04B | $1.20B |
Dividend Yield | — | 7.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Weibo (WB) trades at $7.74, down 3.01% in the last session, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a low P/E of 5.5 and robust net income margin of 21.15%, while cash flow trends improved in 2025. Recent news highlights Q2 2026 results anticipation and AI developments, but competitive pressures persist.
The outlook is mixed; valuation metrics suggest undervaluation with analyst support, but earnings volatility and market sentiment risks require caution. Opportunities lie in cash flow strength and balance sheet health, while risks include user engagement challenges and macroeconomic headwinds in the social media sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
